ALK and non-small cell lung carcinoma: Additionally, among the 1106 patients with ALK‐positive NSCLC treated with crizotinib across PROFILE 1005 and PROFILE 1007, only nine (1%) had a crizotinib dosing modification (dosing interruption and/or dose reduction) due to an adverse event of SB.